knowledge -WSS

knowledge

author：knowledge 2025-10-01 00:47:05 - browse：73

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： UnitedHealth quietly bought dozens of outpatient centers

focus

WSS

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

With psoriasis trial ahead, Alumis raises $259 million

Sen. Paul opposes bill to ban Chinese biotechs

Roivant's CEO is a star, but biotech's black hole persists

Change Healthcare cyberattack prompts Medicare loan program

With psoriasis trial ahead, Alumis raises $259 million

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

New air purifier tech could be key to improving indoor air quality

Why a market frenzy over new weight loss drugs defies logic

BioMarin wins approval for gene therapy to treat hemophilia A

CZI to create biohub to build anti

Malaria cases in Florida and Texas: Here’s what you need to know

Roivant's CEO is a star, but biotech's black hole persists

The high cost of giving birth even with insurance

Headspace, Meta partner to launch VR meditation app for Quest

hotspot

IVF, abortion rights issues kick off Biden’s State of the Union

Health tech investors get more selective as pandemic boom fades

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

STAT Summit: The economic case for universal basic health care

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

CDC marks new Covid

knowledge

focus

explore

focus